Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.50 |
| ▸ | GBA1 | P04062 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | SCN4A | P35499 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3174219 | 1.00 | AOC3 (0.50) | AOC3GBA1HTR2AHRH1TDP1 | |
| SCHEMBL4453664 | 0.82 | AOC3 (0.47) | AOC3GBA1HTR2AHRH1TDP1 | |
| SCHEMBL2295530 | 0.81 | HTR2A (0.64) | AOC3GBA1HTR2AHRH1TDP1 | |
| SCHEMBL1206311 | 0.81 | HTR2A (0.64) | AOC3GBA1HTR2AHRH1TDP1 | |
| SCHEMBL1206312 | 0.81 | HTR2A (0.64) | AOC3GBA1HTR2AHRH1TDP1 | |
| Hydrochloric Acid SCHEMBL20238142 | 0.79 | TDP1 (0.65) | AOC3GBA1HTR2AHRH1TDP1 | |
| Hydrochloric Acid SCHEMBL20238217 | 0.79 | TDP1 (0.65) | AOC3GBA1HTR2AHRH1TDP1 | |
| Hydrochloric Acid SCHEMBL28133965 | 0.79 | TDP1 (0.65) | AOC3GBA1HTR2AHRH1TDP1 | |
| SCHEMBL1205242 | 0.76 | AOC3 (0.63) | AOC3HTR2AHRH1TDP1TAAR1 | |
| SCHEMBL4455539 | 0.73 | SIGMAR1 (0.48) | AOC3GBA1HTR2AHRH1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016374-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016374-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016374-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-2001831-A2 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007113309-A2 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113309-A2 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016374-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | SLC6A5, SLC6A9, SLC6A19 | AOC3 787/4885GBA1 1302/4885HTR2A 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.